Sartorius Grabs MatTek and Visikol: Boosting Drug Development
- Sartorius acquires control over a Swedish micro-warping business
Hey there! Here's a juicy bit of news about Sartorius, a big lab supplier, good folks from Göttingen, Germany. They've just acquired MatTek and Visikol, two companies based in the United States and Slovakia, for approximately €72 million. Sound interesting? Let me tell you more!
MatTek, with headquarters in Ashland, Massachusetts, USA, and production in Bratislava, Slovakia, has 80 employees. They are famous for creating 3D microtissue models that mimic human tissue, which will be a game-changer for Sartorius' cell culture offerings. They generated over $20 million in revenue in 2024, a cool €19.2 million, and will be integrated into Sartorius' lab division in the future.
Now, you might be wondering why Sartorius made this move. Well, the answer is simple: they want to speed up drug development, and MatTek's products and expertise are just what they need! The deal is expected to close in the second quarter of 2025, subject to regulatory approval.
By the way, Sartorius is no newcomer to the game. They're listed on the DAX, the leading index for the German stock market, and this acquisition is a strategic move to enhance their cell culture portfolio with advanced 3D microtissue models and primary cells.
So, there you have it! Sartorius continues to boost its presence in the industry, and with MatTek and Visikol on board, who knows what amazing advancements we'll see in drug development in the future? Let's wait and see, shall we?
Remember, this news tidbit is not just about numbers, it's about innovation, speeding up processes, and revolutionizing the lab world. Keep an eye on Sartorius; they're making waves!
Insights:
- MatTek and Visikol employ over 85 people.
- The acquisition is valued at approximately $80 million.
- MatTek's solutions are designed to integrate closely with Sartorius' existing cell analysis instruments, reagents, and AI models.
- MatTek generated more than $20 million in sales revenue in 2024 with an EBITDA margin similar to that of Sartorius' Lab Products & Services division.
- The transaction is subject to regulatory approval and is expected to close during the second quarter of 2025.
[Sources: 1, 2, 3, 4, 5]
- Sartorius' acquisition of MatTek, valued at around €72 million, includes vocational training for its employees to ensure a smooth integration with Sartorius' lab division by 2025.
- In the pursuit of revolutionizing drug development, Sartorius has incorporated MatTek's expertise in creating 3D microtissue models into their cell culture offerings, mimicking human tissue similar to MatTek's microtissue models.
- MatTek, with over 80 employees, aims to complete the integration of their advanced 3D microtissue models and primary cells into Sartorius' cell analysis instruments, reagents, and AI models before the acquisition is finalized in the second quarter of 2025.
